|Bid||68.49 x 1300|
|Ask||68.89 x 900|
|Day's range||67.67 - 69.72|
|52-week range||35.47 - 121.16|
|Beta (5Y monthly)||1.67|
|PE ratio (TTM)||N/A|
|Earnings date||05 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||109.83|
Years of clinical trials, scrutinized results, and a hoped-for (but not guaranteed) approval from the U.S. Food and Drug Administration are all part of the lifecycle. If clinical trials repeatedly fall short of expectations or an FDA approval fails to materialize, it can be money down the drain for shareholders. Fate Therapeutics (NASDAQ: FATE) is hoping for the latter result for its immunotherapy treatments of B-cell lymphoma -- cancer that forms in a person's white blood cells.
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
We can readily understand why investors are attracted to unprofitable companies. For example, Fate Therapeutics...